World ADC Asia prides itself in being the only dedicated conference that unites the leaders in the antibody drug conjugate field to identify and discuss the critical factors that will influence the next 12 months of your ADC development.
Designed with the leaders from, Daiichi Sankyo, Eisai, Shanghai Miracogen and Immunowork to build an agenda that addresses the biggest challenges, latest data, science and lessons learned from the last year of ADC drug development.
With partnerships being a huge factor in providing momentum of ADC drug development in Asia, this is your perfect opportunity to gain critical insight and valuable partnerships to accelerate the development of your ADC drug pipeline.
This year, 27 ADC thought leaders from the leading ADC organizations will share their ADC secrets.
Don’t miss your opportunity to:
- Hear the rationale for submitting INDs in different countries; how to leverage the strength of Asia and US/Europe with the NMPA, BlissBio and Shanghai Miracogen
- Form lasting connections by engaging directly with 100+ attendees from the leading companies actively developing ADCs in Asia, such as Daiichi Sankyo, Bio-Thera, Sumitomo Dainippon Pharma Co, Seattle Genetics and Mersana
- Learn from the leading Chinese biotech’s who have recently submitted INDs or entered the clinic including Shanghai Miracogen, Blissbio and Genequantum
Leave this meeting equipped with novel approaches to maximizing the therapeutic index of your ADC candidate.